The U.S. Food and Drug Administration has approved Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic ...

With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...

According to Jam Press, a TikToker ( @‌onenevertwhoo_one) who preferred to only be referred to by his social media name, ...

Additionally, the evolving national disease registries lack information about sarcoidosis, and limited awareness among ...

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Can your pet catch COVID-19 or the common cold from you? What can you expect the treatment to be if both you and your pet ...

Researchers at the University Health Network (UHN) and the University of Toronto have developed a skin-based test that can detect signature features of progressive supranuclear palsy (PSP), a rare ...

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...

Shares of Abeona Therapeutics Inc. (ABEO) were in the spotlight on Tuesday afternoon after it announced that the U.S. Food ...